Coulter Partners secures Chief Executive Officer for ArunA Bio

With the appointment of Dr. Sirgo to the senior leadership team, Dr. Steven Stice, co-founder, current CEO and Chief Scientific Officer, will fully focus on directing the company’s research and scientific development efforts. ArunA continues the development of its novel neural exosome platform to optimize the delivery of siRNAs, antibodies, genes and small molecules across the blood brain barrier to improve outcomes for patients with CNS and neurodegenerative disorders including genetic and rare diseases.

Dr. Sirgo most recently served as President and Chief Executive Officer of BioDelivery Sciences, a publicly listed fully integrated specialty pharmaceutical company with a focus in pain/CNS drug development and commercialization. In this role, he successfully raised over $600 million through equity, debt and partnerships and utilized the company’s drug delivery platform to progress three products through FDA approval and commercialization. Prior to joining BioDelivery Services, he spent 16 years in a variety of clinical and commercial leadership positions at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate in Pharmacy from Philadelphia College of Pharmacy and Science.